Brand Intelligence Graph
Company Overview
About Hemab Therapeutics
Hemab Therapeutics is a rare disease biotechnology company developing treatments for rare bleeding disorders that have no approved prophylactic options. The company raised $157 million in an oversubscribed Series C in October 2025, led by Sofinnova Partners and the Qatar Investment Authority (QIA) — a sovereign wealth fund's direct biotech investment signals strategic medical technology interest alongside financial return.
Business Model & Competitive Advantage
The lead program, sutacimig, targets Glanzmann thrombasthenia (GT) — a rare inherited platelet disorder affecting approximately 1 in 1 million people worldwide where platelets cannot aggregate, causing severe bleeding episodes that are life-threatening and quality-of-life-destroying. Sutacimig is advancing to a registration study in 2026, with a potential FDA filing to follow. There are currently zero approved prophylactic treatments for GT, making any approved therapy in this indication an orphan-drug monopoly with strong pricing power.
Competitive Landscape 2025–2026
Hemab's second program, HMB-003, has an IND filing expected in the first half of 2026, targeting another rare coagulation disorder. QIA's participation reflects Qatar's broader strategy of building a healthcare ecosystem — rare disease biotech acquisitions and partnerships are central to that ambition, and QIA's portfolio companies have typically seen follow-on M&A interest from global pharmaceutical companies.
Key Differentiators
Emerging Innovator
Hemab Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Hemab Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Hemab Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Hemab Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Hemab Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →